Avalo Therapeutics annual gross margin
2016
2017
2018
2020
2021
2022
2023
2024
2025
Avalo Therapeutics Gross Margin Growth & History (AVTX)
Avalo Therapeutics's gross margin was 100.00% for fiscal 2025.
View full Avalo Therapeutics company overviewAvalo Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 100.00% | −82.99 pp |
| 2024 | 2024-12-31 | 182.99% | +149.73 pp |
| 2023 | 2023-12-31 | 33.26% | −47.71 pp |
| 2022 | 2022-12-31 | 80.98% | +8.60 pp |
| 2021 | 2021-12-31 | 72.38% | −23.14 pp |
| 2020 | 2020-12-31 | 95.52% | — |
| 2018 | 2018-12-31 | 53.61% | −44.11 pp |
| 2017 | 2017-12-31 | 97.71% | −2.29 pp |
| 2016 | 2016-12-31 | 100.00% | — |
Avalo Therapeutics quarterly gross margin
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | 100.00% | +45.31 pp |
| Q4 2024 | 2024-12-31 | 54.69% | −84.26 pp |
| Q4 2023 | 2023-12-31 | 138.95% | +108.03 pp |
| Q3 2023 | 2023-09-30 | −4.66% | −101.13 pp |
| Q2 2023 | 2023-06-30 | −10.11% | +41.59 pp |
| Q1 2023 | 2023-03-31 | −16.00% | −54.62 pp |
| Q4 2022 | 2022-12-31 | 30.92% | +123.19 pp |
| Q3 2022 | 2022-09-30 | 96.47% | +63.73 pp |
| Q2 2022 | 2022-06-30 | −51.69% | −149.22 pp |
| Q1 2022 | 2022-03-31 | 38.62% | −45.10 pp |
| Q4 2021 | 2021-12-31 | −92.27% | −186.99 pp |
| Q3 2021 | 2021-09-30 | 32.74% | −60.33 pp |
| Q2 2021 | 2021-06-30 | 97.53% | +3.36 pp |
| Q1 2021 | 2021-03-31 | 83.72% | −13.88 pp |
| Q4 2020 | 2020-12-31 | 94.72% | — |
| Q3 2020 | 2020-09-30 | 93.07% | −0.92 pp |
| Q2 2020 | 2020-06-30 | 94.17% | +69.86 pp |
| Q1 2020 | 2020-03-31 | 97.60% | +26.81 pp |
| Q3 2019 | 2019-09-30 | 93.99% | +70.34 pp |
| Q2 2019 | 2019-06-30 | 24.31% | −45.95 pp |
| Q1 2019 | 2019-03-31 | 70.79% | −9.94 pp |
| Q3 2018 | 2018-09-30 | 23.65% | −76.35 pp |
| Q2 2018 | 2018-06-30 | 70.26% | −29.74 pp |
| Q1 2018 | 2018-03-31 | 80.73% | −19.27 pp |
| Q4 2017 | 2017-12-31 | −128.78% | — |
| Q3 2017 | 2017-09-30 | 100.00% | — |
| Q2 2017 | 2017-06-30 | 100.00% | — |
| Q1 2017 | 2017-03-31 | 100.00% | — |
Avalo Therapeutics gross margin trends
Over the last five fiscal years, Avalo Therapeutics's gross margin increased from 95.52% to 100.00%, a change of +4.48 percentage points. The latest reported quarter, Q4 2025, shows 100.00%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Avalo Therapeutics source filings ↗